Molecular Identification of Pathogenetic IdLNF+1 Autoantibody Idiotypes Derived from the (NZB×SWR)F1 Model for Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Molecular Identification of Pathogenetic IdLNF+1 Autoantibody Idiotypes Derived from the (NZB×SWR)F1 Model for Systemic Lupus Erythematosus

Published:2002-11 Issue:3 Volume:19 Page:87-101
ISSN:0896-8411
Container-title:Journal of Autoimmunity
language:en
Short-container-title:Journal of Autoimmunity

Author:

Price Karen,Knupp Corey J.,Tatum Arthur H.,Jiang Feng,Stoll Matthew,Gavalchin Jerrie

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference74 articles.

1. IdLNF1-specific T cell clones accelerate the production of IdLNF1+ IgG and nephritis in SNF1 mice;Knupp;J. Autoimmunity,1995

2. Treatment with antibody reactive with the nephritogenic idiotype, IdLNF1, suppresses its production and leads to prolonged survival of (NZB×SWR) F1 mice;Uner;J. Autoimmunity,1994

3. The NZB×SWR model of lupus nephritis. II. Autoantibodies deposited in renal lesions show a distinctive and restricted idiotypic diversity;Gavalchin;J. Immunol.,1987

4. Idiotype-anti-idiotype network. II. Activation of silent clones by treatment at birth with idiotypes is associated with the expansion of idiotype-specific helper T cells;Rubinstein;J. Exp. Med.,1982

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE;International Immunopharmacology;2012-01

2. Idiotypes;eLS;2011-11-15

3. 17β-Estradiol (E-2) administration to male (NZB × SWR)F1 mice results in increased IdLNF1-reactive memory T-lymphocytes and accelerated glomerulonephritis;Lupus;2011-11-07

4. Animal Models of Systemic Lupus Erythematosus (SLE) and Ex Vivo Assay Design for Drug Discovery;Current Protocols in Pharmacology;2011-06

5. The induction of the lupus phenotype by estrogen is via an estrogen receptor-α-dependent pathway;Clinical Immunology;2010-02